REATA PHARMACEUTICALS

FA Drug Development

Dawn Bir
Chief Commercial Officer

Reata Confidential

Disclaimers

The information is for informational use only.

NAF and Reata encourage all attendees to consult with their healthcare provider for medical advice.

Products mentioned during this presentation does not imply endorsement by NAF.

Friedreich's Ataxia: Ultra-Rare, Progressive, Neuromuscular Disease

- **Ultra-rare genetic disease**
  An estimated 5,000 patients are diagnosed in the U.S.[5]

- **Relentlessly progressive loss of motor function**
  - Typically diagnosed in teens[6], requires mobility aids in twenties[7], mean survival is mid-thirties[8]

- **No approved therapies before now**

[1]Cook A., Br Med Bull. 2017; [2]Poburski D., Biology Open 2016; [3]D'Oria V., Int. J. Mol. Sci. 2013; [4]Paupe V., PLoS ONE 2009; [5]U.S. claims data and projected diagnosed, [6]Rummey C., Neurol Genet 2019; [7]Rummey C., E Clinical Medicine. 2020; [8]Tsou A.Y., J Neurol Sci 2011



FA Community has Worked Diligently to Facilitate Drug Development

- **Better understand mechanism and course of disease**
- **Support research & development through grants and funding**
- **Develop clinically meaningful endpoints**
- **Design robust, viable clinical trials**
- **Consult with FDA on regulatory path**

Developing a New Drug May Take ~12-15 Years



[Friedreich's Ataxia Research Alliance - Participation in Clinical Trials (curefa.org)]

Reata's Journey From Bench to FDA Approval

Early R&D

- Initiated in 2014
- Role of Nrf2 in FA proposed by advocacy group & FA caregiver
- Reata conducts preclinical studies

Clinical Trial Endpoint

- KOLs, FARA, & Reata partner on mFARS use in clinical trials
- FDA consult on study design

MOXIe Clinical Studies

- Positive pivotal data!
- FDA requires more data before New Drug Application (NDA) can be submitted

FA Community Petition

- 74,000 global signatures advocating for FDA review & approval
- 35,000 from the US
- 2,000 from patients

FDA Priority Review

- Add'l data submitted
- Priority Review granted
- Advisory Committee meeting canceled

FDA Approved!

- Reata received FDA approval for the U.S. on Feb 28, 2023
- Rare Disease Day
- 1st & Only Treatment for FA

Visit Us at Booth #1
Sign Up at www.SKYCLARYS.com to Learn More

BOOTH #1

Patients' ROLE in drug development: Be a part of research!

We thank FA patients, their caregivers, advocacy & all